Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous...
Brain
Luminopia Partners with Pokémon to Expand Its Curated Content Library for Pediatric Amblyopia Patients
Children using Luminopia now have access to hundreds of episodes from the original Pokémon animated series, making amblyopia treatment even...
Longevity Takes the Spotlight: Global Wellness Summit Announces First Wave of Trailblazing Speakers for 19th Annual Gathering
From gene editing breakthroughs to AI-driven drug discovery to epigenetic interventions, this year's Summit explores the radical advances reshaping how...
The Brain Aneurysm Foundation Announces its 2025 Research Grant Recipients
Close to $600,000 in Funding Provided to 14 Academic Researchers from Across the US to Advance New Innovations to Predict,...
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
SOLANA BEACH, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...
Cumulus Neuroscience Appoints Robert Ballantine to Board of Directors
BELFAST, Northern Ireland, Sept. 10, 2025 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing...
NeuroKaire launches first-of-its-kind clinical test in the US, expected to dramatically reduce the ‘trial and error’ approach to finding the right antidepressant
NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,...
NeuroKaire launches first-of-its-kind clinical test in the US, expected to dramatically reduce the ‘trial and error’ approach to finding the right antidepressant
NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,...
Understood.org Unveils “Through My Eyes” Immersive Platform, Offering Glimpses Into the Daily Lives of Kids With ADHD, Dyslexia, and Dyscalculia
The free digital tool uses simulations, videos, and expert resources to start conversations and challenge assumptions about learning and thinking...
Understood.org Unveils “Through My Eyes” Immersive Platform, Offering Glimpses Into the Daily Lives of Kids With ADHD, Dyslexia, and Dyscalculia
The free digital tool uses simulations, videos, and expert resources to start conversations and challenge assumptions about learning and thinking...
CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics
Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path...
CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics
Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path...
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed...
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate...
20 Years of the Ubiquitin Revolution: Honoring Nobel Laureate Professor Avram Hershko and the Future of Targeted Protein Degradation
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD)...
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
BrainCo Helps Amputee Showcase Technology at WAIC 2025
BOSTON, Sept. 8, 2025 /PRNewswire/ -- At the 2025 World Artificial Intelligence Conference (WAIC) in August 2025, Gu demonstrated the...
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for...
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology,...
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in...